The historical rank and industry rank for Shanghai Junshi Biosciences Co's EV-to-FCF or its related term are showing as below:
SHJBF'
s EV-to-FCF Range Over the Past 10 Years
Min: -29.03 Med: -12.18 Max: -2.28
Current: -25.06
During the past 10 years, the highest EV-to-FCF of Shanghai Junshi Biosciences Co was -2.28. The lowest was -29.03. And the median was -12.18.
SHJBF's EV-to-FCF is ranked worse than 100% of 333
companies
in the Biotechnology industry
Industry Median: 15.57
vs SHJBF: -25.06
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shanghai Junshi Biosciences Co (OTCPK:SHJBF) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shanghai Junshi Biosciences Co's PE Ratio (TTM) for today is calculated as:
Shanghai Junshi Biosciences Co's share price for today is $3.35.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Shanghai Junshi Biosciences Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.118.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Shanghai Junshi Biosciences Co EV-to-FCF Related Terms
Shanghai Junshi Biosciences Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Shanghai Junshi Biosciences Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Junshi Biosciences Co EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Junshi Biosciences Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Shanghai Junshi Biosciences Co's EV-to-FCF falls into.
Shanghai Junshi Biosciences Co's current Enterprise Value is $4,738.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Shanghai Junshi Biosciences Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-180.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Junshi Biosciences Co (SHJBF) has a EV-to-FCF of -26.28 as of Jul. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Shanghai Junshi Biosciences Co and its competitors. According to the industry distribution chart, Shanghai Junshi Biosciences Co ranks #999999 out of 333 companies in the Biotechnology industry.
Is Shanghai Junshi Biosciences Co's EV-to-FCF too high?
Shanghai Junshi Biosciences Co's current EV-to-FCF is -26.28. Based on the distribution chart, Shanghai Junshi Biosciences Co ranks #999999 out of 333 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Shanghai Junshi Biosciences Co has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Junshi Biosciences Co's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Junshi Biosciences Co ranks #999999 out of 333 companies for EV-to-FCF. This places Shanghai Junshi Biosciences Co in the lower half of its industry. The industry median EV-to-FCF is 15.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.57, based on 333 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Shanghai Junshi Biosciences Co and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Junshi Biosciences Co's current EV-to-FCF is -26.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Junshi Biosciences Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Junshi Biosciences Co (SHJBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $5.63, compared to a current price of $3.35 — trading 40.5% below its estimated fair value. The current EV-to-FCF is -26.28. Shanghai Junshi Biosciences Co's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Shanghai Junshi Biosciences Co (SHJBF), the current EV-to-FCF is -26.28 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Junshi Biosciences Co (SHJBF) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Junshi Biosciences Co stock appears to be undervalued.
The current stock price of $3.35 is trading 40.5% below its estimated GF Value™ of $5.63.
GuruFocus considers Shanghai Junshi Biosciences Co to be Significantly Undervalued.
Key valuation signals for SHJBF:
EV-to-FCF: -26.28
GF Value™: $5.63 vs. price of $3.35 (40.5% below fair value)
No single metric tells the full story. See the SHJBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Junshi Biosciences Co Business Description
Shanghai Junshi Biosciences Co Ltd is mainly involved in the discovery, development, and commercialisation of therapeutic drugs. It focuses on the development and commercialization of several kinds of drugs, ranging from monoclonal antibodies to various drug modalities, including small molecules, ADCs, bi-specific or multi-specific antibodies, fusion proteins, nucleic acid drugs, and vaccines, as well as the exploration of next-generation therapies, including those for cancer and autoimmune diseases. The Group's portfolio includes commercialized drugs such as Tuoyi, Junmaikang, Mindewei, and Junshida, as well as products in clinical studies or in the marketing application stage. Geographically, it derives maximum revenue from Mainland China, and the rest from USA, India, and other markets.
66GF Score
Get the complete analysis for SHJBF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHJBF has been successfully added to your 
